Hsbc Holdings PLC Has $206,000 Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Hsbc Holdings PLC lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 26.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 27,972 shares of the company’s stock after buying an additional 5,764 shares during the period. Hsbc Holdings PLC’s holdings in Recursion Pharmaceuticals were worth $206,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Wedmont Private Capital raised its stake in Recursion Pharmaceuticals by 11.8% in the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after purchasing an additional 2,000 shares in the last quarter. Interchange Capital Partners LLC raised its position in shares of Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after buying an additional 2,349 shares in the last quarter. Amalgamated Bank lifted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the period. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $26,000. Finally, Victory Capital Management Inc. increased its stake in Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after acquiring an additional 2,598 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $6.04, for a total value of $120,800.00. Following the sale, the chief executive officer now owns 762,656 shares in the company, valued at approximately $4,606,442.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Christopher Gibson sold 20,000 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $6.04, for a total value of $120,800.00. Following the sale, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at approximately $4,606,442.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $7.32, for a total transaction of $83,792.04. Following the sale, the director now owns 7,167,110 shares of the company’s stock, valued at approximately $52,463,245.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 263,129 shares of company stock valued at $1,826,444 in the last three months. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ:RXRX opened at $6.11 on Friday. The stock’s 50-day moving average is $6.83 and its 200-day moving average is $8.06. Recursion Pharmaceuticals, Inc. has a 1-year low of $4.97 and a 1-year high of $15.74. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.72 billion, a P/E ratio of -3.82 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The business had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative net margin of 755.37% and a negative return on equity of 79.47%. The company’s revenue was up 30.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.38) earnings per share. Equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on RXRX shares. Jefferies Financial Group cut their target price on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research note on Tuesday, September 3rd. KeyCorp reduced their price objective on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Leerink Partners lowered their target price on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $9.40.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.